Variable effects of alpha v suppression on VEGFR-2 expression in endothelial cells of different vascular beds

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 975-982

  Dardik, Rima ^a,b   Livnat, Tami ^a,b   Seligsohn, Uri ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

v suppression; v 3 and v 5 inhibitors; v 3 and v 5 integrins; Angiogenesis; siRNA

Indexed keywords

ALPHAVBETA5 INTEGRIN; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; E BOX ELEMENT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; UPREGULATION;

CAPILLARIES; CELL DIVISION; CELLS, CULTURED; E-BOX ELEMENTS; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTEGRIN ALPHAV; INTEGRIN ALPHAVBETA3; ORGAN SPECIFICITY; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RECEPTORS, VITRONECTIN; RNA, MESSENGER; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70449598259     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-10-0687     Document Type: Article

References (29)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
3. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001; 2001: RE21.
4. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
5. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-1822.
6. Fu Y, Ponce ML, Thill M, et al. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci 2007; 48: 5184-5190. (Pubitemid 351260930)
7. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003; 39: 917-926. (Pubitemid 36428623)
8. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6: 3056-3061.
9. Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 2008; 17: 1225-1235.
10. Maubant S, Saint-Dizier D, Boutillon M, et al. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 2006; 108: 3035-3044. (Pubitemid 44776942)
11. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002; 8: 27-34.
12. Reynolds AR, Reynolds LE, Nagel TE, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res 2004; 64: 8643-8650.
13. Bader BL, Rayburn H, Crowley D, et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998; 95: 507-519. (Pubitemid 28533307)
14. McCarty JH, Monahan-Earley RA, Brown LF, et al. Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol Cell Biol 2002; 22: 7667-7677.
15. Dejong V, Degeorges A, Filleur S, et al. The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun. Oncogene 1999; 18: 3143-3151. (Pubitemid 29261235)
16. Hata Y, Duh E, Zhang K, et al. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J Biol Chem 1998; 273: 19294-19303. (Pubitemid 28366330)
17. Jackson TA, Taylor HE, Sharma D, et al .Vascular endothelial growth factor receptor-2: counter-regulation by the transcription factors, TFII-I and TFII-IRD1. J Biol Chem 2005; 280: 29856-29863. (Pubitemid 41177063)
18. Sheppard D. Endothelial integrins and angiogenesis: not so simple anymore. J Clin Invest 2002; 110: 913-914.
19. Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 2003; 314: 131-144.
20. Wilkinson-Berka JL, Jones D, Taylor G, et al. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2006; 47: 1600-1605.
21. Taverna D, Moher H, Crowley D, et al. Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc Natl Acad Sci U S A 2004; 101: 763-768. (Pubitemid 38121032)
22. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 8: 918-921.
23. Reynolds AR, Hart IR, Watson AR, et al. .Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009; 15: 392-400.
24. Borges E, Jan Y, Ruoslahti E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem 2000; 275: 39867-39873. (Pubitemid 32064606)
25. Soldi R, Mitola S, Strasly M, et al. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J 1999; 18: 882-892. (Pubitemid 29082268)
26. Chi JT, Chang HY, Haraldsen G, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 2003; 100: 10623-10628. (Pubitemid 37140079)
27. McCarty JH, Lacy-Hulbert A, Charest A et al. Selective ablation of alphav integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal degeneration and premature death. Development 2005; 132: 165-176. (Pubitemid 40207976)
28. Graef T, Steidl U, Nedbal W, et al. Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis. Angiogenesis 2005; 8: 361-372. (Pubitemid 43312271)
29. Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-4117.